Sam Brusco, Associate Editor06.26.23
Medtronic and Allurion, a company aiming to end obesity, have begun a pilot agreement. The partnership will grow access to Allurion’s artificial intelligence (AI)-powered weight loss program through a sales agency agreement in the Central and Eastern Europe, Middle East, and Africa (CEMA) region.
The partnership helps Allurion offer the Allurion Balloon and boost utilization of the Allurion Iris AI platform to manage bariatric surgery patients by using Medtronic channels during the collaboration.
The Allurion Balloon is a swallowable, procedure-less gastric balloon for weight loss. The Allurion Program combines the balloon with the Allurion Virtual Care Suite remote patient monitoring powered by the Iris AI platform and company’s proprietary behavior change program. The Virtual Care Suite also comes as a standalone product to customize, monitor, and manage weight loss therapy for patients, independent of their treatment plan (gastric balloon, surgical, medical, or nutritional.)
In February the company proclaimed its intention to go public via a business combo with Compute Health. This agreement builds on this existing partnership.
"We are thrilled to join forces with Medtronic to expand access to our weight loss program. Medtronic has exceptional distribution capabilities across a number of different channels that can augment our base business,” Dr. Shantanu Gaur, Allurion’s founder and CEO told the press. “We also believe this partnership will help accelerate adoption of our Iris AI Platform as a standalone offering to streamline the management of patients undergoing bariatric surgery and potentially improve outcomes, further cementing our position as a leader in AI and weight management.”
The partnership helps Allurion offer the Allurion Balloon and boost utilization of the Allurion Iris AI platform to manage bariatric surgery patients by using Medtronic channels during the collaboration.
The Allurion Balloon is a swallowable, procedure-less gastric balloon for weight loss. The Allurion Program combines the balloon with the Allurion Virtual Care Suite remote patient monitoring powered by the Iris AI platform and company’s proprietary behavior change program. The Virtual Care Suite also comes as a standalone product to customize, monitor, and manage weight loss therapy for patients, independent of their treatment plan (gastric balloon, surgical, medical, or nutritional.)
In February the company proclaimed its intention to go public via a business combo with Compute Health. This agreement builds on this existing partnership.
"We are thrilled to join forces with Medtronic to expand access to our weight loss program. Medtronic has exceptional distribution capabilities across a number of different channels that can augment our base business,” Dr. Shantanu Gaur, Allurion’s founder and CEO told the press. “We also believe this partnership will help accelerate adoption of our Iris AI Platform as a standalone offering to streamline the management of patients undergoing bariatric surgery and potentially improve outcomes, further cementing our position as a leader in AI and weight management.”